**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 60563

**Manuscript Type:** SYSTEMATIC REVIEWS

**Clinical features of SARS-CoV-2-associated encephalitis and meningitis amid COVID-19 pandemic**

Huo L *et al*. SARS-CoV-2-associated encephalitis and meningitis

Liang Huo, Kai-Li Xu, Hua Wang

**Liang Huo,** Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Kai-Li Xu,** Department of Pediatric Neurology, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, Henan Province, China

**Kai-Li Xu,** Department of Pediatric Neurology, Henan Children’s Hospital, Zhengzhou 450018, Henan Province, China

**Hua Wang,** Department of Pediatric Neurology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Author contributions:** Huo L designed the study, analyzed the data, and drafted the paper; Xu KL analyzed the data and drafted the paper; Wang H collected the data; all authors read and approved the final manuscript.

**Supported by** Liaoning Provincial Department of Education Scientific Research Project, No. QNZR2020012; Henan Neural Development Engineering Research Center for Children Foundation, No. SG201905; and the National Key Research and Development Program of China, No. 2016YFC1306203.

**Corresponding author: Liang Huo, MD, PhD, Assistant Professor,** Department of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. huol@sj-hospital.org

**Received:** November 5, 2020

**Revised:** December 1, 2020

**Accepted:** December 23, 2020

**Published online:** February 16, 2021

**Abstract**

BACKGROUND

Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, numerous studies have been published on SARS-CoV-2-related encephalitis/meningitis, but it has not been established if there are specific clinical characteristics of encephalitis/meningitis associated with SARS-CoV-2 infection.

AIM

To identify the specific clinical features of cases of encephalitis/meningitis associated with SARS-CoV-2 infection in the context of this virus infection pandemic and investigate their relationship with SARS-CoV-2 infection.

METHODS

We searched PubMed, and included single case reports and case series with full text in English, reporting original data of coronavirus disease-19 (COVID-19) patients with encephalitis/meningitis and a confirmed recent SARS-CoV-2 infection. Clinical data were extracted.

RESULTS

We identified 22 articles (18 single case reports and 4 case series) reporting on a total of 32 encephalitis/meningitis patients with confirmed SARS-CoV-2 infection. SARS-CoV-2 infection was confirmed through reverse transcriptase-polymerase-chain-reaction (RT-PCR) in 96.88% of cases. A total of 22 (68.75%) patients had symptoms of SARS-CoV-2 infection in about 1 wk (7.91 d) preceding the onset of neurologic symptoms. The most common neurological symptoms were consciousness disturbance (59.38%), seizure (21.88%), delirium (18.75%), and headache (18.75%). Four cases were confirmed by positive RT-PCR results in cerebrospinal fluid (CSF), one was confirmed by positive RT-PCR results in postoperative brain tissue, and one by the presence of SARS-CoV-2 antibodies in CSF. The mainly damaged targets identified by neuroimaging included the temporal lobe (15.63%), white matter (12.5%), frontal lobe (9.38%), corpus callosum (9.38%), and cervical spinal cord (9.38%). Eighty percent of patients had electroencephalograms that showed a diffuse slow wave. Twenty-eight (87.5%) patients were administered with specific treatment. The majority (65.63%) of patients improved following systemic therapy.

CONCLUSION

Encephalitis/meningitis is the common neurological complication in patients with COVID-19. The appropriate use of definitions and exclusion of potential similar diseases are important to reduce over-diagnosis of SARS-CoV-2 associated encephalitis or meningitis.

**Key Words:** COVID-19; SARS-CoV-2; Encephalitis; Meningitis; Clinical features; System review

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Huo L, Xu KL, Wang H. Clinical features of SARS-CoV-2-associated encephalitis and meningitis amid COVID-19 pandemic. *World J Clin Cases* 2021; 9(5): 1058-1078

URL: https://www.wjgnet.com/2307-8960/full/v9/i5/1058.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i5.1058

**Core Tip:** Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, although many cases or cases series of SARS-CoV-2-related encephalitis/meningitis have been reported, the specific clinical characteristics of SARS-CoV-2-relatedencephalitis/meningitis have not been systematically described. We retrospectively analyzed and summarized the comprehensive clinical characteristics of SARS-CoV-2-related encephalitis/meningitis, including demographic characteristics, diagnostic investigations, and outcomes.

**INTRODUCTION**

Coronavirus disease-19 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In December 2019, the first coronavirus outbreak was detected in China, which quickly spread around the world and became a global health emergency[1]. As of November 4, 2020, there were over 47690000 confirmed COVID-19 cases and 1210000 reported deaths in 216 countries worldwide, according to the World Health Organization (WHO) report.

The Centers for Disease Control has termed that many cases feature multisystem inflammatory syndrome in the setting of SARS-CoV-2 positive diagnostic testing[2]. SARS-CoV-2 may cause severe neurological complications, such as encephalopathy, encephalitis, stroke, acute disseminated encephalomyelitis, Guillain Barré syndrome, and skeletal muscle involvement[3]. Up to 85% of patients with SARS-CoV-2 have minor neurological symptoms[4]. Up to 20% of patients with SARS-CoV-2 require admission to the intensive care unit (ICU) because of neurological problems, and these patients have a higher mortality[5]. Neurological symptoms of SARS-CoV-2 include headache, decreased responsiveness, anosmia, myalgia, ageusia, hypogeusia, or dysgeusia[6,7].

Encephalitis refers to acute, diffuse, inflammatory lesions in the brain parenchyma caused by pathogens, including neuronal damage and nerve tissue lesions. The common symptoms of encephalitis include headache, fever, vomiting, convulsions, focal neurological deficits, and consciousness disorders[8]. Meningitis is an infection of the meninges, and its clinical manifestations include fever, vomiting, headache, and meningeal symptoms. Cerebrospinal fluid (CSF) examination of meningitis usually shows changes in inflammation[9].

SARS-CoV-2 and SARS-CoV are very similar in structure, and both enter human cells after binding to the angiotensin converting enzyme 2 (ACE2) receptor. For this reason, ACE2-expressing cells, like neurons or glial cells, may be the target cells for SARS-CoV-2 infection[10]. Recently, Moriguchi *et al*[9] reported the first case of meningitis/encephalitis that was caused by SARS-CoV-2. The direct evidence for confirmation of SARS-CoV-2 associated encephalitis/meningitis was the detection of SARS-CoV-2 RNA in CSF[11]. There are possibly two principal routes for SARS-CoV-2 to affect the central nervous system (CNS): Hematogenous dissemination or retrograde dissemination of neurons *via* indirect routes. Nevertheless, the underlying neurotropic mechanism of SARS-CoV-2 has not yet been established[12-14].

The sensitivity of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of SARS-CoV-2 to detect acute COVID-19 in appropriately treated nasopharyngeal swabs is high, but current data are limited to evaluate the sensitivity of this technique in CSF in patients with neurological disease[15]. Due to the time limit of transmission of COVID-19, its CSF titer may be extremely low, which makes it difficult to diagnose SARS-CoV-2-related encephalitis[16].

Since the SARS-CoV-2 epidemic, numerous studies have been published on SARS-CoV-2-related encephalitis/meningitis[11,16-18], but it has not been established if there are specific clinical characteristics of encephalitis/meningitis after SARS-CoV-2 based on published cases or case series. Therefore, we conducted a systematic and retrospective review of all published studies, which includes cases or case series, on SARS-CoV-2-related encephalitis/meningitis, and gave a comprehensive overview of clinical features, including demographic characteristics, diagnostic investigations, and outcomes, of SARS-CoV-2-related encephalitis/meningitis patients.

**MATERIALS AND METHODS**

We conducted a systematical search of the medical literature using MEDLINE (accessed from PubMed) and Google Scholar from December 01, 2019 to September 13, 2020 for related published articles. The types of literature included isolated case reports, case series, and cohort studies. We used search terms, “COVID-19 and encephalitis, meningitis” and “SARS-CoV-2 and encephalitis, meningitis”. Full-text articles were obtained from journals’ websites. We analysed demographics, neurological symptoms and signs, subtype, blood test, CSF, neuroimaging, electroencephalogram (EEG), treatment, and outcome characteristics of COVID-19 patients complicated with encephalitis/meningitis. We also described the pathogenesis of COVID-19-associated encephalitis and meningitis.

**RESULTS**

We identified 22 articles that were published between January 1, 2020 and September 13, including data from 30 isolated cases of confirmed COVID-19 patients complicated with encephalitis/meningitis. Tables 1 and 2 summarize the detailed demographic and clinical characteristics of patients with SARS-CoV-2-associated encephalitis/meningitis[2,9,16-38].

Of the 32 individual patients with SARS-CoV-2-associated encephalitis or meningitis, 20 (62.5%) were male, and 12 (37.5%) were female, with a male-to-female ratio of 1.67:1. Their median age was 45.37 years (age range, 8-75 years). A total of 31 (96.88%) definite cases of SARS-CoV-2 infection were those confirmed by positive RT-PCR results, and one (11.4%) case was confirmed by the presence of SARS-CoV-2 antibodies. The time between reported viral syndrome and confirmed COVID-19 was 6 d (range, 2-15 d). A total of 22 (68.75%) patients had symptoms of SARS-CoV-2 infection in about 1 wk (7.91 d) preceding the onset of neurological symptoms (Table 2). Fever (*n* = 16, 55.17%), cough (*n* = 13, 44.83%), and dyspnea (*n* = 11, 37.93%) were the most frequently documented initial symptoms of SARS-CoV-2 infection, followed by diarrhea (*n* = 4, 13.79%). Median time between reported viral syndrome and onset of neurological symptoms was 7.91 d (range, 1-21 d). Consciousness disturbance (*n* = 19, 59.38%), seizure (*n* = 7, 21.88%), delirium (*n* = 6, 18.75%), and headache (*n* = 6, 18.75%) were the most frequently documented neurological symptoms of SARS-CoV-2-associated encephalitis/meningitis, followed by altered mental status (*n* = 3, 9.38%). A total of four (12.5%) definite cases of SARS-CoV-2-associated encephalitis/meningitis were those confirmed by positive RT-PCR results in CSF, one (3.13%) was confirmed by positive RT-PCR results in postoperative brain tissue, and one (3.13%) was confirmed by the presence of SARS-CoV-2 antibodies in CSF.

The clinical and laboratory features of the patients with the SARS-CoV-2-associated encephalitis/meningitis are summarized in Tables 3 and 4[2,9,16-31,33,37-38]. Nineteen (59.36%) patients were determined to have encephalitis, five (15.63%) were classified as having meningitis, five (15.63%) had meningoencephalitis, two (6.25%) had encephalomyelitis, and one (3.13%) had rhombencephalitis and myelitis. As shown by neuroimaging, the encephalitis/meningitis caused by SARS-CoV-2 mainly damaged the temporal lobe (*n* = 5, 15.63%), frontal lobe (*n* = 3, 9.38%), corpus callosum (*n* = 3, 9.38%), white matter (*n* = 3, 12.5%), cervical spinal cord (*n* = 3, 12.5%), thalami (*n* = 2, 9.38%), and cortex (*n* = 2, 6.25%).

In this group of SARS-CoV-2-associated encephalitis/meningitis patients, only 22 had chest radiogram performed, and of these, 81.82% (18/22) had positive findings. Surprisingly, 18.18% (4/22) of patients’ chest radiograms were negative. Twenty-one (65.63%) patients underwent blood test analysis. Six (28.57%) patients had a low/normal white blood cell (WBC) count, ten (47.62%) had a high WBC count, four (19.05%) had lymphopenia, 14 (66.67%) had high C-reactive protein (CRP), ten (57.14%) had high D-dimer, and eight (38.1%) had high ferritin. Thirty-one (96.88%) patients underwent CSF analysis. Thirteen (13/22, 59.09%) patients with CSF data had an increased protein level, nine (9/23, 39.13%) had an increased WBC level, and two (2/5, 40%) had increased intracranial pressure. One patient had a positive anti-NMDA antibody in CSF (Tables 3 and 4).

In this group of SARS-CoV-2-associated encephalitis/meningitis patients, 31 (96.88%) had neuroimaging performed, and of these 61.29% (18/31) had abnormal findings of brain damage. Approximately 38.71% (11/31) of patients had no significant findings. Ten (31.25%) patients received EEG to assess unexplained consciousness disturbance, myoclonus, seizure, headache, altered mental status, dysarthria, and responsiveness. Among these ten patients, eight (80%) had EEGs that showed a diffuse slow wave, and two (20%) had EEGs that showed a focal epileptic wave. These EEG findings suggest that CNS injury may be related to SARS-CoV-2 infection in these patients.

Twenty-eight (87.5%) patients were administered with specific treatment, of whom 22 (78.57%) received antibiotics, 14 (50%) received antiretroviral drugs, seven (25%) received corticoids, six (21.43%) received plasmapheresis treatment, six (21.43%) received intravenous immunoglobulin (IVIg), six (21.43%) received anticonvulsant medications, and one each received surgery, interleukin-1 receptor antagonist, and traditional Chinese medicine. Twenty-nine (90.63%) of patients had recorded outcomes; the prognosis was good in 21 (65.63%) patients and poor in five (15.64%), and three (9.38%) patients died (Tables 1 and 4).

**DISCUSSION**

SARS-CoV-2 involves multiple organs including the central and peripheral nervous system[15]. In a series of studies in Wuhan, 78 of 214 COVID-19 patients, recruited over 4 wk, developed neurological manifestations. These patients tended to be more severely affected, older, and with more complications, and for some, the neurological symptom was the first presentation of COVID-19[32]. The widespread effects of COVID-19 include neurological disorders, but there have been no detailed clinical reports of their nature to date[33,34]. Neurological complications caused by SARS-CoV-2 are similar to those caused by other coronaviruses, especially severe acute respiratory syndrome (SARS) in 2003 and Middle East acute respiratory syndrome in 2012. Cases described in those reports include encephalopathy, encephalitis, stroke, hemorrhage, acute disseminated encephalomyelitis, and Guillain-Barré syndrome[35,36]. About 80% of COVID-19 patients have no or only mild symptoms, especially in children and young adults. Up to 20% patients with SARS-CoV-2 infection will develop some degrees of severe symptoms[15]. Severe patients were more likely to have neurological complications such as encephalitis, meningitis, stroke, and encephalopathy than non-severe patients[10]. Most patients with SARS-CoV-2 infection were severe or critically ill, and they required ICU treatment and mechanical ventilation. Lung abnormalities were found in almost all patients with SARS-CoV-2-associated encephalitis[1]. Therefore, early diagnosis of viral encephalitis is essential to improve the prognosis of COVID-19 patients.

In this study, we systematically reviewed the clinical data of SARS-CoV-2-associated encephalitis/meningitis that were identified in the context of the COVID-19 global pandemic. To our knowledge, this is the first largest comprehensive retrospective review of any published studies, including case or case series, that have been conducted to assess the role of SARS-CoV-2 infection in patients diagnosed with encephalitis/meningitis during the SARS-CoV-2 outbreak. We systematically described the epidemiological, clinical, radiology, laboratory, therapeutic, and prognostic outcomes. This latest review focuses on clinical characteristics that may help clinicians identify potential patients early and begin timely and appropriate treatment to improve the end result.

Encephalitis/meningitis is the neurological complication in patients with SARS-CoV-2 infection[7]. During the ongoing pneumonia epidemic, a few isolated case (patients 4, 12, and 22) reports of SARS-CoV-2 associated encephalitis/meningitis, has been detected the SARS-CoV-2 in CSF[17,37-39]. The medical team of Beijing Ditan Hospital confirmed the presence of SARS-CoV-2 in the CSF of COVID-19 patients through genome sequencing, thus clinically confirming SARS-CoV-2 viral encephalitis[19]. This provides a solid foundation for coronavirus encephalitis. Transcribrial spread of SARS-CoV-2 to the brain is also supported by the fact that hyposmia/anosmia is one of the earliest symptoms with which patients usually present[6]. Anosmia and abnormal brain function can help distinguish it from other encephalopathy[9].

Currently, most of the patients with SARS-CoV-2 infection and neurological complications are elderly people, and most of them are more than 50 years old. This age group is more likely to have complications and develop into severe disease[40,41]. In our review, however, COVID-19 patients with encephalitis or meningitis can be found in all age groups, and the main age group is over 30 years old (68.75%). The incidence of SARS-CoV-2-associated encephalitis or meningitis is relatively low in children and adolescents (31.25%), which may be related to the relatively mild illness of COVID-19 in children and adolescents. The cases were determined as SARS-CoV-2-associated encephalitis or meningitis according to WHO criteria (SARS-CoV-2 RNA PCR positive results from nasopharyngeal swab, CSF, or pathological specimen)[42].

Encephalitis is an infection or inflammation that involves the brain and surrounding tissues. Meningitis is an infection or inflammation that affects the meninges and spinal cord[43]. SARS-CoV-2-associated encephalitis/meningitis is always preceded by commoner clinical features about 1 wk ago (7.91 d, range 1-21 d), like fever (55.17%), cough (44.83%), dyspnea (37.93%), and diarrhea (13.79%). Most COVID-19 patients who develop encephalitis/meningitis complications are referred to ICU for hospitalization[1]. Symptoms of viral meningitis typically include fever, neck pain, photophobia, and/or photophobia. Symptoms of viral encephalitis may include abnormal brain function (altered mental state, personality change, and behavioral or verbal abnormalities), movement disorders, and focal neurological signs, like hemiplegia, facioplegia, or abnormal sensation. Seizures may occur in both viral meningitis and encephalitis[12]. Like other viruses, the main clinical symptoms of SARS-CoV-2-associated encephalitis/meningitis are consciousness disturbance (59.38%), seizure (21.88%), delirium (18.75%), and headache (18.75%). Laboratory indicators of COVID-19 showed lymphocytosis, elevated D-dimer, and altered ground glass opacity on chest imaging[41]. Among inflammatory markers in patients with SARS-CoV-2 associated encephalitis/meningitis, high WBC count (47.62%), high CRP (66.67%) and D-dimer (57.14%), and raised ferritin (38.1%) were reported in many cases.

To date, virus-induced immune response leading to inflammatory damage of the CNS and direct invasion are the two main pathophysiological mechanisms of SARS-CoV-2-associated encephalitis[43,44]. SARS-CoV-2 enters cells by binding to ACE-2 receptors. The ACE-2 receptor is expressed not only in the lungs but also in the CNS[45,46]. The combination of SARS-CoV-2 and ACE2 receptor may lead to increased secretion of inflammatory factors such as TNF-alpha, IL-1, and IL-6, which may be the cause of neuropsychiatric symptoms[47]. In the absence of evidence of direct viral invasion, SARS-CoV-2-associated encephalitis may be associated with immune-mediated inflammatory mechanisms (patient 3)[15]. Although the human respiratory system is the target organ of human coronavirus, SARS-CoV-2 also has the ability to directly invade the nervous system[48]. It has been demonstrated in rodent models that SARS-CoV-2 invades the CNS and causes neuronal death[49]. Based on the known neurotropism of previous SARS-CoV strains, SARS-CoV-2 also can spread to the CNS directly, which could access the CNS *via* olfactory pathways or the bloodstream, causing meningitis and encephalitis[50,51].

By definition, SARS-CoV-2-associated encephalitis/meningitis is an inflammatory process, and supporting evidence includes the presence of COVID-19 patients with CSF pleocytosis and elevated protein[38]. Definitive evidence about direct neuroinvasiveness of SARS-CoV-2 would include SARS-CoV-2 RNA PCR positive tests in CSF, SARS-CoV-2-specific antibodies positive tests in CSF, or SARS-CoV-2 RNA or antigen positive tests in brain tissue obtained at autopsy or biopsy[52]. Although more and more cases of SARS-associated encephalitis have been reported, few (25%) actually meet the strict criteria for direct SARS-CoV-2-associated encephalitis. In the majority of reported patients with COVID-19-associated encephalopathy, CSF was reported as normal (Table 1). Thus, detailed nervous system physical examination, auxiliary examination, and positive rate of SARS-CoV-2 detection in CSF are very important to provide direct neurotropic evidence of SARS-CoV-2[53].

In SARS-CoV-2-associated encephalitis, infection or inflammation can involve any part of the brain, especially the temporal lobe (15.63%), white matter (12.5%), frontal lobe (9.38%), and corpus callosum (9.38%). Neuroimaging abnormalities, in SARS-CoV-2-associated encephalitis, usually present with high T2/FLAIR signal hyperintensity in the subcortical white matter or other parts of brain injury. There are also many COVID-19 patients (38.71%) who do not have significant neuroimaging changes in encephalitis[54,55].

In the majority of patients (8/10, 80%) with SARS-CoV-2-associated encephalitis, the EEG manifestation was diffuse slow waves, and some patients present with a focal epileptic wave or generalized delta activity. Slow speed and theta activity in EEGs of COVID-19 patients are not necessarily direct evidence of encephalitis and may be related to depressants, drowsiness, muzziness, hypoxia, and other CNS depressive entities[56]. However, it is important to note that when EEGs show monomorphic biphasic high amplitude delta waves associated with occasional myoclonic muscular activity, this may suggest that brain damage is associated with the direct effect of COVID-19 itself[57].

Patients with encephalitis generally need ICU care and occasionally mechanical ventilation. More than 50% of patients with SARS-CoV-2-associated encephalitis/meningitis were treated with antibiotics and antiviral drugs (especially hydroxychloroquine, 42.86%). Some patients were also treated with IVIg and corticoids. Anticonvulsant medications were used in the patients with seizure. Dogan *et al*[26] reported plasma exchange in a series of six patients with SARS-CoV-2-associated autoimmune meningoencephalitis.

In general, the presence of neurological disease in COVID-19 patients is associated with higher mortality, disturbance of consciousness, refractory epilepsy, and severe physical disability. However, we reviewed published case reports and found that most COVID-19 patients with encephalitis or meningitis (21/32, 65.63%) improved after systematic treatment. Three patients died and other patients remained in ICU.

**CONCLUSION**

In summary, given the high neurotropism potential of SARS-CoV-2, the lack of reports of COVID-19 patients complicated with encephalitis or meningitis is surprising[58]. Encephalitis/meningoencephalitis may cause direct damage to the brainstem respiratory center, which may be one of the reasons for the extremely high fatality rate in patients with COVID-19. Detailed biopsy or autopsy neuropathology studies should answer this question[59]. From the perspective of infectious diseases of the CNS, the cases of SARS-CoV-2-associated encephalitis that were reported lack direct evidence of SARS invading the nervous system, while the cases of COVID-19 patients who were tested for CSF while excluding other potential diagnoses were only accidental reports. Therefore, we should conduct appropriate investigations to exclude other identified brain infections and parainfluenza before attributing a condition to SARS CoV-2[60]. The appropriate use of definitions and exclusion of potential similar diseases are important to reduce over-diagnosis of SARS-CoV-2-associated encephalitis or meningitis.

**ARTICLE HIGHLIGHTS**

***Research background***

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has quickly spread around the world and become a global health emergency. There were over 47690000 confirmed coronavirus disease-19 (COVID-19) cases and 1210000 reported deaths in 216 countries worldwide.

***Research motivation***

SARS-CoV-2 may cause severe neurological complications, such as encephalopathy and encephalitis. However, it has not been established if there are specific clinical characteristics of encephalitis/meningitis after SARS-CoV-2.

***Research objectives***

The objective of this study was to identify specific clinical features of cases of encephalitis/meningitis associated with SARS-CoV-2 infection in the context of this virus pandemic and investigate their relationship with SARS-CoV-2 infection.

***Research methods***

We conducted a search of the medical literature using MEDLINE (accessed from PubMed) and Google Scholar from December 1, 2019 to September 13, 2020 through terms “COVID-19 and encephalitis, meningitis” and “SARS-CoV-2 and encephalitis, meningitis”. Then we analyzed clinical features of COVID-19 patients complicated with encephalitis/meningitis in these articles.

***Research results***

We identified 22 articles that included a total of 32 encephalitis/meningitis patients with confirmed SARS-CoV-2 infection. Approximately 68.75% had symptoms of SARS-CoV-2 infection in about 1 wk preceding the onset of neurological symptoms. The most common neurological symptoms were consciousness disturbance, seizure, delirium, and headache. The mainly damaged targets identified by neuroimaging included the temporal lobe, white matter, frontal lobe, corpus callosum, and cervical spinal cord (9.38%). Eighty percent of patients had EEGs that showed a diffuse slow wave, and 65.63% of patients improved following systemic therapy.

***Research conclusions***

Encephalitis/meningitis is the common neurological complication in patients with COVID-19. From the perspective of infectious diseases of the central nervous system, the cases of SARS-CoV-2-associated encephalitis that were reported lack direct evidence of SARS invading the nervous system, while the cases of COVID-19 patients who were tested for cerebrospinal fluid while excluding other potential diagnoses were only accidental reports. The appropriate use of definitions and exclusion of potential similar diseases are important to reduce over-diagnosis of SARS-CoV-2-associated encephalitis or meningitis.

***Research perspectives***

We should conduct appropriate investigations to exclude other identified brain infections and parainfluenza before attributing a condition to SARS-CoV-2. The appropriate use of definitions and exclusion of potential similar diseases are important to reduce over-diagnosis of SARS-CoV-2-associated encephalitis or meningitis.

**ACKNOWLEDGEMENTS**

The authors would like to thank Professor Zheng LQ, at The Department of Medical Statistics, Library in Shengjing Hospital of China Medical University, for help with statistical analysis. Useful suggestions given by Professor Wang HQ of Perking University Aerospace School of Clinical Medicine are also acknowledged.

**REFERENCES**

1 **Panariello A**, Bassetti R, Radice A, Rossotti R, Puoti M, Corradin M, Moreno M, Percudani M. Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report. *Brain Behav Immun* 2020; **87**: 179-181 [PMID: 32454137 DOI: 10.1016/j.bbi.2020.05.054]

2 **Greene AG**, Saleh M, Roseman E, Sinert R. Toxic shock-like syndrome and COVID-19: Multisystem inflammatory syndrome in children (MIS-C). *Am J Emerg Med* 2020; **38**: 2492.e5-2492.e6 [PMID: 32532619 DOI: 10.1016/j.ajem.2020.05.117]

3 **Tian W**, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, Wooster L, Rotter JI, Guo X, Malhotra R. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Med Virol* 2020; **92**: 1875-1883 [PMID: 32441789 DOI: 10.1002/jmv.26050]

4 **Ahmed MU**, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM, Karim AH, Sattar A. Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. *Front Neurol* 2020; **11**: 518 [PMID: 32574248 DOI: 10.3389/fneur.2020.00518]

5 **Fotuhi M**, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. *J Alzheimers Dis* 2020; **76**: 3-19 [PMID: 32538857 DOI: 10.3233/JAD-200581]

6 **Román GC**, Spencer PS, Reis J, Buguet A, Faris MEA, Katrak SM, Láinez M, Medina MT, Meshram C, Mizusawa H, Öztürk S, Wasay M; WFN Environmental Neurology Specialty Group. The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. *J Neurol Sci* 2020; **414**: 116884 [PMID: 32464367 DOI: 10.1016/j.jns.2020.116884]

7 **Lapostolle F**, Schneider E, Vianu I, Dollet G, Roche B, Berdah J, Michel J, Goix L, Chanzy E, Petrovic T, Adnet F. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. *Intern Emerg Med* 2020; **15**: 813-817 [PMID: 32474850 DOI: 10.1007/s11739-020-02379-z]

8 **Ellul M**, Solomon T. Acute encephalitis - diagnosis and management. *Clin Med (Lond)* 2018; **18**: 155-159 [PMID: 29626021 DOI: 10.7861/clinmedicine.18-2-155]

9 **Moriguchi T**, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shimada S. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis* 2020; **94**: 55-58 [PMID: 32251791 DOI: 10.1016/j.ijid.2020.03.062]

10 **Zhou Z**, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. *J Neurol* 2020; **267**: 2179-2184 [PMID: 32458193 DOI: 10.1007/s00415-020-09929-7]

11 **Garg RK**, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: A review. *J Med Virol* 2020 [PMID: 32558956 DOI: 10.1002/jmv.26207]

12 **Desforges M**, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, Talbot PJ. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? *Viruses* 2019; **12**: 14 [PMID: 31861926 DOI: 10.3390/v12010014]

13 **Swanson PA 2nd**, McGavern DB. Viral diseases of the central nervous system. *Curr Opin Virol* 2015; **11**: 44-54 [PMID: 25681709 DOI: 10.1016/j.coviro.2014.12.009]

14 **Desforges M**, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. *Virus Res* 2014; **194**: 145-158 [PMID: 25281913 DOI: 10.1016/j.virusres.2014.09.011]

15 **Koralnik IJ**, Tyler KL. COVID-19: A Global Threat to the Nervous System. *Ann Neurol* 2020; **88**: 1-11 [PMID: 32506549 DOI: 10.1002/ana.25807]

16 **Ye M**, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. *Brain Behav Immun* 2020; **88**: 945-946 [PMID: 32283294 DOI: 10.1016/j.bbi.2020.04.017]

17 **Efe IE**, Aydin OU, Alabulut A, Celik O, Aydin K. COVID-19-Associated Encephalitis Mimicking Glial Tumor. *World Neurosurg* 2020; **140**: 46-48 [PMID: 32479911 DOI: 10.1016/j.wneu.2020.05.194]

18 **Wang M**, Li T, Qiao F, Wang L, Li C, Gong Y. Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report. *Medicine (Baltimore)* 2020; **99**: e21428 [PMID: 32898993 DOI: 10.1097/MD.0000000000021428]

19 **Hayashi M**, Sahashi Y, Baba Y, Okura H, Shimohata T. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. *J Neurol Sci* 2020; **415**: 116941 [PMID: 32474220 DOI: 10.1016/j.jns.2020.116941]

20 **Benameur K**, Agarwal A, Auld SC, Butters MP, Webster AS, Ozturk T, Howell JC, Bassit LC, Velasquez A, Schinazi RF, Mullins ME, Hu WT. Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020. *Emerg Infect Dis* 2020; **26**: 2016-2021 [PMID: 32487282 DOI: 10.3201/eid2609.202122]

21 **McAbee GN**, Brosgol Y, Pavlakis S, Agha R, Gaffoor M. Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child. *Pediatr Neurol* 2020; **109**: 94 [PMID: 32586676 DOI: 10.1016/j.pediatrneurol.2020.04.013]

22 **Afshar H**, Yassin Z, Kalantari S, Aloosh O, Lotfi T, Moghaddasi M, Sadeghipour A, Emamikhah M. Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case. *Mult Scler Relat Disord* 2020; **43**: 102216 [PMID: 32464585 DOI: 10.1016/j.msard.2020.102216]

23 **Wong PF**, Craik S, Newman P, Makan A, Srinivasan K, Crawford E, Dev D, Moudgil H, Ahmad N. Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection. *Clin Med (Lond)* 2020; **20**: 293-294 [PMID: 32371417 DOI: 10.7861/clinmed.2020-0182]

24 **Duong L**, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. *Brain Behav Immun* 2020; **87**: 33 [PMID: 32305574 DOI: 10.1016/j.bbi.2020.04.024]

25 **Le Guennec L**, Devianne J, Jalin L, Cao A, Galanaud D, Navarro V, Boutolleau D, Rohaut B, Weiss N, Demeret S. Orbitofrontal involvement in a neuroCOVID-19 patient. *Epilepsia* 2020; **61**: e90-e94 [PMID: 32589794 DOI: 10.1111/epi.16612]

26 **Dogan L**, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, Afsar N. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series. *Brain Behav Immun* 2020; **87**: 155-158 [PMID: 32389697 DOI: 10.1016/j.bbi.2020.05.022]

27 **Pilotto A**, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, Nocivelli S, Pezzini A, Focà E, Caruso A, Leonardi M, Pasolini MP, Gasparotti R, Castelli F, Ashton NJ, Blennow K, Zetterberg H, Padovani A. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. *Ann Neurol* 2020; **88**: 423-427 [PMID: 32418288 DOI: 10.1002/ana.25783]

28 **Bernard-Valnet R**, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, Cerutti-Sola J, Rossetti AO, Du Pasquier R. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. *Eur J Neurol* 2020; **27**: e43-e44 [PMID: 32383343 DOI: 10.1111/ene.14298]

29 **Abdel-Mannan O**, Eyre M, Löbel U, Bamford A, Eltze C, Hameed B, Hemingway C, Hacohen Y. Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children. *JAMA Neurol* 2020; **77**: 1-6 [PMID: 32609336 DOI: 10.1001/jamaneurol.2020.2687]

30 **Yin R**, Feng W, Wang T, Chen G, Wu T, Chen D, Lv T, Xiang D. Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. *J Med Virol* 2020; **92**: 1782-1784 [PMID: 32293714 DOI: 10.1002/jmv.25888]

31 **Poyiadji N**, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. *Radiology* 2020; **296**: E119-E120 [PMID: 32228363 DOI: 10.1148/radiol.2020201187]

32 **Mao L**, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020; **77**: 683-690 [PMID: 32275288 DOI: 10.1001/jamaneurol.2020.1127]

33 **Paterson RW**, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambreanu L, Vivekanandam V, Khoo A, Geraldes R, Chinthapalli K, Boyd E, Tuzlali H, Price G, Christofi G, Morrow J, McNamara P, McLoughlin B, Lim ST, Mehta PR, Levee V, Keddie S, Yong W, Trip SA, Foulkes AJM, Hotton G, Miller TD, Everitt AD, Carswell C, Davies NWS, Yoong M, Attwell D, Sreedharan J, Silber E, Schott JM, Chandratheva A, Perry RJ, Simister R, Checkley A, Longley N, Farmer SF, Carletti F, Houlihan C, Thom M, Lunn MP, Spillane J, Howard R, Vincent A, Werring DJ, Hoskote C, Jäger HR, Manji H, Zandi MS. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain* 2020; **143**: 3104-3120 [PMID: 32637987 DOI: 10.1093/brain/awaa240]

34 **Umapathi T**, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, Lee CC, Lim PL, Ponnudurai K, Chuah KL, Tan PH, Tai DY, Ang SP. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). *J Neurol* 2004; **251**: 1227-1231 [PMID: 15503102 DOI: 10.1007/s00415-004-0519-8]

35 **Tsai LK**, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. *Acta Neurol Taiwan* 2005; **14**: 113-119 [PMID: 16252612]

36 **Kim JE**, Heo JH, Kim HO, Song SH, Park SS, Park TH, Ahn JY, Kim MK, Choi JP. Neurological Complications during Treatment of Middle East Respiratory Syndrome. *J Clin Neurol* 2017; **13**: 227-233 [PMID: 28748673 DOI: 10.3988/jcn.2017.13.3.227]

37 **Al-Olama M**, Rashid A, Garozzo D. COVID-19-associated meningoencephalitis complicated with intracranial hemorrhage: a case report. *Acta Neurochir (Wien)* 2020; **162**: 1495-1499 [PMID: 32430637 DOI: 10.1007/s00701-020-04402-w]

38 **Domingues RB**, Mendes-Correa MC, de Moura Leite FBV, Sabino EC, Salarini DZ, Claro I, Santos DW, de Jesus JG, Ferreira NE, Romano CM, Soares CAS. First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. *J Neurol* 2020; **267**: 3154-3156 [PMID: 32564153 DOI: 10.1007/s00415-020-09996-w]

39 **Huang YH**, Jiang D, Huang JT. SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis. *Brain Behav Immun* 2020; **87**: 149 [PMID: 32387508 DOI: 10.1016/j.bbi.2020.05.012]

40 **Zhang JJ**, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; **75**: 1730-1741 [PMID: 32077115 DOI: 10.1111/all.14238]

41 **Jordan RE**, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ* 2020; **368**: m1198 [PMID: 32217618 DOI: 10.1136/bmj.m1198]

42 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

43 **Bookstaver PB**, Mohorn PL, Shah A, Tesh LD, Quidley AM, Kothari R, Bland CM, Weissman S. Management of Viral Central Nervous System Infections: A Primer for Clinicians. *J Cent Nerv Syst Dis* 2017; **9**: 1179573517703342 [PMID: 28579869 DOI: 10.1177/1179573517703342]

44 **Troyer EA**, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. *Brain Behav Immun* 2020; **87**: 34-39 [PMID: 32298803 DOI: 10.1016/j.bbi.2020.04.027]

45 **Natoli S**, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. *Eur J Neurol* 2020; **27**: 1764-1773 [PMID: 32333487 DOI: 10.1111/ene.14277]

46 **Das G**, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. *ACS Chem Neurosci* 2020; **11**: 1206-1209 [PMID: 32320211 DOI: 10.1021/acschemneuro.0c00201]

47 **Netland J**, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 2008; **82**: 7264-7275 [PMID: 18495771 DOI: 10.1128/JVI.00737-08]

48 **Rothan HA**, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun* 2020; **109**: 102433 [PMID: 32113704 DOI: 10.1016/j.jaut.2020.102433]

49 **Vavougios GD**. Host proteases as determinants of coronaviral neurotropism and virulence. *Brain Behav Immun* 2020; **87**: 27 [PMID: 32272221 DOI: 10.1016/j.bbi.2020.04.010]

50 **Durrant DM**, Ghosh S, Klein RS. The Olfactory Bulb: An Immunosensory Effector Organ during Neurotropic Viral Infections. *ACS Chem Neurosci* 2016; **7**: 464-469 [PMID: 27058872 DOI: 10.1021/acschemneuro.6b00043]

51 **Dubé M**, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. *J Virol* 2018; **92**: e00404-18 [PMID: 29925652 DOI: 10.1128/JVI.00404-18]

52 **Varatharaj A**, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles JP, Manji H, Al-Shahi Salman R, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R, Pett SL, Galea I, Thomas RH, Michael BD; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry* 2020; **7**: 875-882 [PMID: 32593341 DOI: 10.1016/S2215-0366(20)30287-X]

53 **Baig AM**, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci* 2020; **11**: 995-998 [PMID: 32167747 DOI: 10.1021/acschemneuro.0c00122]

54 **Mahammedi A**, Saba L, Vagal A, Leali M, Rossi A, Gaskill M, Sengupta S, Zhang B, Carriero A, Bachir S, Crivelli P, Paschè A, Premi E, Padovani A, Gasparotti R. Imaging of Neurologic Disease in Hospitalized Patients with COVID-19: An Italian Multicenter Retrospective Observational Study. *Radiology* 2020; **297**: E270-E273 [PMID: 32437313 DOI: 10.1148/radiol.2020201933]

55 **Radmanesh A**, Raz E, Zan E, Derman A, Kaminetzky M. Brain Imaging Use and Findings in COVID-19: A Single Academic Center Experience in the Epicenter of Disease in the United States. *AJNR Am J Neuroradiol* 2020; **41**: 1179-1183 [PMID: 32467191 DOI: 10.3174/ajnr.A6610]

56 **Smith SJ**. EEG in neurological conditions other than epilepsy: when does it help, what does it add? *J Neurol Neurosurg Psychiatry* 2005; **76** Suppl 2: ii8-i12 [PMID: 15961870 DOI: 10.1136/jnnp.2005.068486]

57 **Hepburn M**, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A, Newey CR. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? *Neurocrit Care* 2020; 1-5 [PMID: 32462412 DOI: 10.1007/s12028-020-01006-1]

58 **Steardo L**, Steardo L Jr, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. *Acta Physiol (Oxf)* 2020; **229**: e13473 [PMID: 32223077 DOI: 10.1111/apha.13473]

59 **Schirinzi A**, Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Ciavarella D, Palmieri G, Pozzessere P, Procacci V, Di Serio F, Santacroce L. New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of *Human epididymis secretory protein 4* (HE4) and the Innate Immunity of the Oral Cavity and Respiratory Tract. *Microorganisms* 2020; **8**: 1718 [PMID: 33147871 DOI: 10.3390/microorganisms8111718]

60 **Romoli M**, Jelcic I, Bernard-Valnet R, García Azorín D, Mancinelli L, Akhvlediani T, Monaco S, Taba P, Sellner J; Infectious Disease Panel of the European Academy of Neurology. A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details. *Eur J Neurol* 2020; **27**: 1712-1726 [PMID: 32503088 DOI: 10.1111/ene.14382]

**Footnotes**

**Conflict-of-interest statement:** All the authors declare that they have no conflicts of interest to report.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 5, 2020

**First decision:** November 23, 2020

**Article in press:** December 23, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Shi Y **S-Editor:** Huang P **L-Editor:** Wang TQ **P-Editor:** Liu JH

**Table 1 Demographic and clinical characteristics of acute neurologic illness among patients with confirmed encephalitis/meningitis with evidence of severe acute respiratory syndrome coronavirus 2 infection**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Ref.** | **Age/Sex** | **Area** | **Past medical history** | **Viral syndrome** | **Diagnosis of COVID-19** | **TVC (d)** | **Neurological symptoms** | **Neurological signs** | **TVN (d)** | **Subtype** | **Primary target** | **Treatment** | **Outcome** |
| 1 | 16 | NA/male | China | N/A | Fever, shortness of breath, myalgia | (+) RT-PCR/PS | N/A | Consciousness confusion | (+) Meningeal irritation signs (including nuchal rigidity, Kernig sign and Brudzinski sign) and extensor plantar response | 14 | ME | N/A | Supportive therapy (mannitol infusion, oxygen therapy), arbidol | Good: Consciousness was completely clear, hospital discharged |
| 2 | 9 | 24 yr/male | Japan | N/A | Headache, fatigue, fever | (-) RT-PCR/NPS | N/A | Consciousness disturbance, seizures | (+) Neck stiffness | 9 | ME | Right lateral ventricle, mesial temporal lobe, hippocampus | N/A | N/A |
| 3 | 2 | 23 yr/male | Italy | Substance abuse | Psychomotor agitation, thought disorganization, persecutory delusions, auditory hallucinations, anxiety, insomnia | (+) RT-PCR/PS | N/A | Dysphagia, dyskinesias, autonomic instabilities | Non responsive to commands, non-verbal, despite being able to move all his extremities and reacting to noxious stimuli | 8 | E | N/A | High doses of DEX, IVIg | Good: Clinical conditions are ameliorating |
| 4 | 17 | 35 yr/female | Turkey | N/A | Mild flu-like complaints | (+) RT-PCR/PS | N/A | Headache, nausea, dizziness, seizure | N/A | 14 | E | Left anterior temporal lobe | Left anterior temporal lobectomy | Good: No post-operative neurological deficits, symptoms improved completely |
| 5 | 36 | 36 yr/male | United Arab Emirates | N/A | Fever, headache, myalgia, cough, diarrhea, vomiting | (+) RT-PCR/PS | 5 | Drowsiness, consciousness confusion | (+) Mild neck stiffness | 5 | ME | Supratentorial leptomeningeal, right frontal lobe | N/A | Poor: The patient’s neurological symptoms was not improved |
| 6 | 19 | 75 yr/male | Japan | Alzheimer’s disease | Diarrhea | (+) RT-PCR/PS | 6 | Left hand kinetic tremor, walking instability, urinary incontinence | (+) Finger-to-nose test; (+) ataxic gait was observed | 6 | E | Corpus callosum | Sulbactam/ampicillin, favipiravir, corticosteroid pulse, ciclesonide, meropenem | Dead |
| 7 | 20 | 31 yr/female | United States | Sickle cell disease | Progressive dyspnea | (+) RT-PCR/NPS | 5 | Paralysis | Coma | 11 | EM | Right cerebral hemisphere, cervical spinal cord | Hydroxychloroquine, peramivir | Dead |
| 8 | 20 | 34 yr/male | United States | Hypertension | Fever, shortness of breath, cough | (+) RT-PCR/NPS | 2 | Consciousness disturbance, myoclonus | Absent corneal and gag reflexes, absent withdrawal to painful stimuli | 9 | E | Corpus callosum | Hydroxychloroquine | N/A |
| 9 | 20 | 64 yr/male | United States | Hypertension | Cough, dyspnea, fever | (+) RT-PCR/NPS | N/A | Myoclonus | Absent oculocephalic reflex and withdrawal to pain, diminished deep tendon reflexes | N/A | E | Right temporal lobe | Hydroxychloroquine | Good: Hospital discharged without major neurologic sequelae |
| 10 | 21 | 11 yr/male | United States | N/A | Generalized weakness, fever | (+) RT-PCR/PS | 3 | Status epilepticus | N/A | 3 | E | Frontal lobe | Anticonvulsant medications | Good: Recovery |
| 11 | 22 | 39 yr/female | Iran | N/A | Fever, myalgia, dry cough | (+) Anti-SARS- CoV-2-IgM, IgG in serum | 10 | Drowsiness, decline unconsciousness, seizure, headaches | N/A | 10 | E | Temporal lobe, pontine, thalami | Broad-spectrum IV antibiotics, hydroxychloroquine, atazanavir, IVIg, levetiracetam, methylprednisolone | Good: Normal consciousness, no diplopia or other abnormal findings |
| 12 | 37 | 42 yr/female | Brazil | N/A | Coryza, nasal obstruction | (-) RT-PCR/NPS | N/A | Paresthesias (left upper limb, left hemithorax, and hemiface) | Hypoesthesia in left upper limb, left hemithorax, and hemiface | 21 | EM | Cervical spinal cord | Corticosteroids | Good: Recovery |
| 13 | 23 | 40 yr/male | United Kingdom | Hypertension, glaucoma | Fever, progressive dyspnea, cough, diarrhea | (+) RT-PCR/NPS | 11 | Unsteady gait, diplopia, oscillopsia, limb ataxia, altered sensation in right arm, hiccups and dribbling when eating or drinking | Facial weakness, reduced tongue movements, limb ataxia | 13 | RE, myelitis | Brain stem; cervical spine | Gabapentin | Good: Neurological symptoms improved steadily and hospital discharged |
| 14 | 24 | 41 yr/female | United States | Diabetes | Headache, fever | (+) RT-PCR/PS | 3 | Headache, seizure | (+) Neck stiffness, photophobia | 2 | ME | N/A | Antibiotics, acyclovir, anti-epileptic medication, hydroxychloroquine | Good: The patient's mentation improved and was able to ambulate, eat and use the bathroom, but the hallucinations remained intermittently |
| 15 | 25 | 69 yr/male | France | Diabetes, hypertension | Cough, fever, anosmia | (+) RT-PCR/tracheal aspirate | 5 | Status epilepticus | N/A | 5 | E | Right frontal lobe | IVIg | Good: Improved |
| 16 | 26 | 49 yr/male | Turkey | N/A | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | E | White matter, cortical | Plasmapheresis treatment, LOP/RIT, AZI, CEF | Good: Consciousness was improved |
| 17 | 26 | 59 yr/male | Turkey | Hypertension | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | E | White matter, cortical | Plasmapheresis treatment, AZI, HC, FAV | Good: Consciousness was improved |
| 18 | 26 | 59 yr/male | Turkey | Hypertension, diabetes, obesity | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | M | N/A | Plasmapheresis treatment, AZI, HC, FAV | Dead: Cardiac arrest |
| 19 | 26 | 51 yr/female | Turkey | Hypertension, diabetes | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | M | N/A | Plasmapheresis treatment, AZI, HC, FAV | Good: Consciousness was improved |
| 20 | 26 | 55 yr/male | Turkey | Hypertension | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | M | N/A | Plasmapheresis treatment, AZI, HC, FAV | Poor: Subsequent infection |
| 21 | 26 | 22 yr/male | Turkey | Autism | Dyspnea | (+) RT-PCR/PS | N/A | Consciousness disturbance, delirium | N/A | N/A | E | White matter | Plasmapheresis treatment, AZI, HC, FAV | Good: Consciousness was improved |
| 22 | 33 | 40 yr/female | United States | Obesity, diabetes mellitus | Fever | (+) RT-PCR/NPS | N/A | Syncope | N/A | 1 | E | N/A | Hydroxychloroquine | Good: Recovery without neurological deficits |
| 23 | 27 | 60 yr/male | United Kingdom | N/A | Fever, cough, cognitive fluctuations | (+) RT-PCR/NPS | 5 | Irritability, confusion, asthenia, consciousness | (+) Palmomental and glabella reflexes, mutism, (+) moderate nuchal rigidity, severe akinetic syndrome | 1 | E | N/A | Lopinavir/ritonavir, hydroxychloroquine, ampicillin, acyclovir | Good: Normal neurological examination and hospital discharged |
| 24 | 28 | 64 yr/female | Switzerland | N/A | Weakness, cough, myalgia | (+) RT-PCR/NPS | N/A | Tonico-clonic seizure | Disoriented, attention deficit, bilateral grasping, psychotic symptoms (hyper-religiosity with mystic delusions, visual hallucinations), averbal and motor perseverations | 6 | E | N/A | Clonazepam, valproate, acyclovir | Good: Improved |
| 25 | 28 | 67 yr/female | Switzerland | N/A | Cough | (+) RT-PCR/NPS | N/A | Headache, syncope | Motor perseverations, bilateral grasping, aggressiveness, left hemianopia and sensory hemineglect | 18 | E | N/A | Ceftriaxone, amoxicillin, acyclovir | Good: Neurological symptoms resolved, except for a mild headache, hospital discharged |
| 26 | 29 | 8 yr/male | South Asian | N/A | Fever, abdominal pain, palmar rash, vomiting | (+) RT-PCR/NPS | N/A | Confused, agitated, headache | (+) Meningeal irritation signs (including nuchal rigidity, Kernig sign and Brudzinski sign), generalized proximal weakness | 1 | ME | Corpus callosum | IVIg, dexamethasone, anakinra | Poor: Still inpatient, wheelchair bound |
| 27 | 29 | 9 yr/male | Caribbean | N/A | Fever, palmar rash, vomiting | (+) RT-PCR/NPS | N/A | Confused, ataxia, dysarthria, headache | Urinary retention, bilateral proximal leg weakness | 1 | E | Corpus callosum | N/A | Good: Hospital discharged |
| 28 | 30 | 64 yr/male | China | Health | Fever, cough | (+) RT-PCR/PS | 15 | Lethargic, unresponsive | (+) Meningeal irritation signs (nuchal rigidity, Kernig sign, Brudzinski sign), consciousness alternating between lethargy and irritability, responses to questions were incorrect, (+) ankle clonus, Babinski sign and Chaddock sign | 14 | M | N/A | Oxygen inhalation, arbidol, ribavirin, traditional Chinese medicine | Good: Clear consciousness, limb reflexes were relatively active, left lower limb was positive for pathological signs |
| 29 | 31 | 50 yr/female | United States | N/A | Cough, fever | (+) RT-PCR/PS | 2 | Altered mental status | N/A | 2 | E | Thalami, temporal lobe, insular lobe | IVIg | N/A |
| 30 | 18 | 56 yr/male | China | N/A | N/A | (+) RT-PCR/PS | N/A | Consciousness confusion | N/A | N/A | M | N/A | N/A | Good: Neurological symptoms gradually disappeared |
| 31 | 33 | 65 yr/female | United Kingdom | N/A | N/A | (+) RT-PCR/NPS | N/A | Reduced  consciousness | N/A | N/A | E | N/A | 1 g IVMP 3 d, oral prednisolone taper, levetiracetam, clonazepam | Poor: Incomplete, partial recovery |
| 32 | 33 | 66 yr/female | United Kingdom | N/A | N/A | (+) RT-PCR/NPS | N/A | Reduced  consciousness | N/A | N/A | E | Upper pons, limbic lobes, medial thalami, subcortical cerebral white matter | 1 g IVMP 3 d then oral prednisolone taper, IVIg | Poor: Incomplete, partial recovery |

NA: Not available; M: Male; F: Female; (+): Positive; TVC: Time between reported viral syndrome and confirmed coronavirus disease-19; TVN: Time between reported viral syndrome and onset of neurological symptoms (d); PS: Pharyngeal swab; NPS: Nasopharyngeal swab; E: Encephalitis; M: Meningitis; ME: Meningoencephalitis; EM: Encephalomyelitis; RE: Rhombencephalitis; WBCs: White blood cells; CRP: C-reactive protein; LDH: Lactate dehydrogenase; CSF: Cerebrospinal fluid; LOP: Lopinavir; RIT: Ritonavir; AZI: Azitromisin; HC: Hydroxychloroquine; CEF: Ceftriaxone; FAV: Faviripavir; IL-6: Interleukin-6; MRI: Magnetic resonance imaging; AlbQ: Albumin quotient; IVIg: Intravenous immune globulin.

**Table 2 Clinical and demographic characteristics of the 32 coronavirus disease-19 patients with encephalitis/meningitis**

|  |  |
| --- | --- |
| **Characteristic** | **Value (*n* = 32)** |
| Median age (range), yr | 45.37 (8-75) |
| Male sex, *n* (%) | 20 (62.5) |
| Female sex, *n* (%) | 12 (37.5) |
| Time between reported viral syndrome and confirmed COVID-19 (*n* = 12) | 6 (2-15) |
| General symptoms before the onset of the encephalitis/meningitis, *n* (%) | 29 (96.67) |
| Fever | 16 (55.17) |
| Cough | 13 (44.83) |
| Dyspnea | 11 (37.93) |
| Diarrhea | 4 (13.79) |
| Myalgia | 4 (13.79) |
| Generalized weakness | 3 (10.34) |
| Headache | 3 (10.34) |
| Vomiting | 3 (10.34) |
| Nasal obstruction | 2 (6.90) |
| Palmar rash | 2 (6.90) |
| Abdominal pain | 1 (3.45) |
| Anosmia | 1 (3.45) |
| Cognitive fluctuations | 1 (3.45) |
| Insomnia | 1 (3.45) |
| Psychological abnormalities | 1 (3.45) |
| Time between reported viral syndrome and onset of neurological symptoms | 7.91 (1-21) |
| Neurological symptoms, *n* (%) | 32 (100) |
| Consciousness disturbance | 19 (59.38) |
| Seizure | 7 (21.88) |
| Delirium | 6 (18.75) |
| Headache | 6 (18.75) |
| Altered mental status | 3 (9.38) |
| Ataxia | 2 (6.25) |
| Drowsiness | 2 (6.25) |
| Dysphagia | 2 (6.25) |
| Myoclonus | 2 (6.25) |
| Paresthesias | 2 (6.25) |
| Syncope | 2 (6.25) |
| Unsteady gait | 2 (6.25) |
| Autonomic instabilities | 1 (3.13) |
| Diplopia | 1 (3.13) |
| Dizziness | 1 (3.13) |
| Dysarthria | 1 (3.13) |
| Dyskinesias | 1 (3.13) |
| Kinetic tremor | 1 (3.13) |
| Nausea | 1 (3.13) |
| Oscillopsia | 1 (3.13) |
| Paralysis | 1 (3.13) |
| Urinary incontinence | 1 (3.13) |
| SARS-CoV-2 infection diagnostic category, *n* (%) |  |
| Nasopharyngeal swab/PT-PCR | 28 (87.5) |
| SARS-CoV-2 IgM (Serum) | 1 (3.13) |
| SARS-CoV-2 IgG (Serum) | 1 (3.13) |
| Tracheal aspirate/PT-PCR | 1 (3.13) |
| PCR for SARS-CoV-2 on CSF | 4 (12.5) |
| PCR for SARS-CoV-2 in Postoperative brain histopathology | 1 (3.13) |
| SARS-CoV-2 antibody (CSF) | 3 (9.38) |

COVID-19: Coronavirus disease-19; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; RT-PCR: Reverse transcriptase-polymerase chain reaction; CSF: Cerebrospinal fluid.

**Table 3 Auxiliary examination of acute neurologic illness among patients with confirmed encephalitis/meningitis with evidence of severe acute respiratory syndrome coronavirus 2 infection**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Ref.** | **Chest radiogram** | **Blood test** | **CSF finding** | **SARS-CoV-2 in CNS** | **Neuroimaging** | **EEG** |
| 1 | 16 | CT showed multiple subpleural ground glass opacities | Low WBC count (3.3 × 109/L) and lymphopenia (0.8 × 109/L) | WBC1 cell/mm3, protein 0.27 g/L, ADA 0.17 U/L and sugar 3.14 mmol/L; the evidence of bacterial or tuberculous infection (-) | Anti-SARS-CoV-2 IgM /IgG in CSF (-) | Skull CT was normal | N/A |
| 2 | 9 | CT showed that there was small ground glass opacity on the right superior lobe and both sides of the inferior lobe | High WBC, neutrophil dominant, relatively low lymphocytes; high CRP | Pressure was greater than 320 mmH2O, cell count 12 cells/mm3, mononuclear 10 cells/mm3 and polymorphonuclear 2 cells/mm3. Anti- HSV 1 and varicella-zoster IgM antibodies (-) | SARSCoV-2 RNA in CSF (-) | MRI showed hyperintensity along the wall of right lateral ventricle and hyperintense signal changes in the right mesial temporal  lobe and hippocampus | N/A |
| 3 | 2 | CT showed patchy bi-basilar consolidations | WBC 10.49 × 109/L, Neut 6.63 × 109/L, Lym 2.86 × 109/L, PLT 83 × 109/L; CRP 55 mg/L | WBC 960 cells/mm3, glucose 70 mg/dL, proteins 65.4 mg/dL; HSV/EBV/CMV/ VZV-DNA (-); enterovirus (-); Ab anti Ca++Channel/AMPA1, 2 /CASPR 2 /LGI1 (-); Ab anti NMDAR (+) | SARS-CoV-2 RNA in CSF (-) | Neuroradiology did not show significant findings | The EEG showed theta activity at 6 Hz, unstable, non-reactive to visual stimuli. No significant asymmetries were seen |
| 4 | 17 | N/A | N/A | N/A | SARSCoV-2 RNA in Postoperative brain histopathology (+) | MRI showed hyperintense signal in the left temporal lobe in T2 and T2 FLAIR imaging | N/A |
| 5 | 36 | X-ray did not show any pathological findings | high WBC count 12.9 × 109/L; high procalcitonin 0.10 ng/mL; high D-dimer 0.790 mg/L | N/A | SARS-CoV-2 RNA PCR in CSF (+) | A right frontal intracerebral hematoma associated with subarachnoid hem orrhage in the ipsilateral sylvian fissure and frontal and temporal lobes; a thin, acute subdural hematoma was also evident. The hematoma appeared surrounded by edema and caused midline shift. Bilateral supratentorial leptomeningeal increased enhancement was detected | N/A |
| 6 | 19 | CT showed ground glass opacities in the bilateral inferior lobes | WBC count 5.96 × 109/L, lymphocytopenia 1.1 × 109/L, PLT 143 × 109/L; CRP 53.2 mg/L | N/A | N/A | MRI revealed an abnormal hyperintensity in the SCC on diffusion-weighted image | N/A |
| 7 | 20 | CT showed right lower lobe infiltrate | N/A | Pressure 30 cmH2O, nucleated 115 cells/mm3, erythrocytes 7374 cells/mm3, protein > 2 g/L; nucleated cell count remained strongly increased even after correction for the traumatic tap (approximately 1 nucleated cell/700 erythrocytes) | Markedly increased levels of IgM for SARS-CoV-2 S1 and E proteins in CSF, SARS-CoV-2 RNA in CSF (-) | MRI showed non-enhancing cerebral edema and diffusion weighted imaging abnormalities predominantly involving the right cerebral hemisphere, as well as brain herniation. An occlusive thrombus was identified in the right internal carotid artery, and edema was also identified in the cervical spinal cord | N/A |
| 8 | 20 | CT showed bilateral, diffuse ground glass infiltrates | N/A | Pressure 48 cmH2O, no pleocytosis, erythrocytes 27 cells/mm3, a mildly increased protein level | Markedly increased levels of IgM for SARS-CoV-2 S1, SARS-CoV-2 RNA in CSF (-) | MRI showed a non-enhancing hyperintense lesion within the splenium of the corpus callosum on fluid- attenuated inversion recovery and diffusion weighted imaging sequences | EEG showed diffuse slowing with a suggestion that the myoclonus was seizure-related |
| 9 | 20 | CT showed multifocal, patchy, ground glass opacities | N/A | Normal opening pressure; levels of nucleated cells, erythrocytes, and protein within reference levels; increased glucose level | Markedly increased levels of IgM for SARS-CoV-2 S1, SARS-CoV-2 RNA in CSF (-) | MRI showed an equivocal non-enhancing area of fluid-attenuated inversion recovery abnormality in the right temporal lobe | N/A |
| 10 | 21 | N/A | N/A | Red cell 921 cells/mm3, WBC 16 cells/mm3, neutrophils 8%, protein 0.97 g/L, glucose 92 mg/dL | SARS-CoV-2 RNA in CSF (-) | CT was negative | EEG noted frontal intermittent delta activity |
| 11 | 22 | CT showed multiple peripheral patchy ground-glass opacities | ANA = 2.7, positive; WBC 20 × 109/L, Neut 15 × 109/L, Lym 0.8 × 109/L, PLT 168 × 109/L; CRP 480 mg/L | Protein 0.19 g/L, glucose 61 mg/Dl with no white or red blood cells; HSV-DNA (-) | SARS-CoV-2 RNA in CSF (-) | MRI revealed T2- FLAIR high signal intensities in bilateral thalami, medial temporal and pons. Corresponding areas in T1 images were hypo-signal | N/A |
| 12 | 37 | CT was normal | Blood cell counts, transaminases, bilirubin, CPK, coagulogram, electrolytes, renal function, and CRP were all normal | WBC 1 cell/mm3, protein 0.32 g/L, glucose 68 mg/dL | SARS-CoV-2 RNA in CSF (+) | Brain MRI was normal; cervical spinal cord MRI showed a small left lateral ventral lesion with T2/STIR hypersignal, measuring about 0.4 cm in its sagittal plane | N/A |
| 13 | 23 | X-ray showed a right lower zone consolidation | WBC 7.0 × 109/L, lymphocytes 1.2 × 109/L; high CRP 50 mg/L; high GGT 107 U/L, high ALT 88 U/L | Protein 0.423 g/L with no rise in white cells and negative bacterial cultured | Low volume sample could be obtained and PCR for SARS-CoV-2 RNA was not possible | MRI of the brain and cervical spine suggested an inflammatory rhombencephalitis/myelitis, the increased signal lesion in the right inferior cerebellar peduncle, extending to a small portion of the upper cord. The lesion measured 13 mm in maximum cross-sectional area and 28 mm in longitudinal extent. There was swelling at the affected tissue and associated micro-haemorrhage | N/A |
| 14 | 24 | X-ray and CT were normal | WBC 7.1 × 109/L | white cells 70 cells/mm3 with 100% lymphocyte, protein 0.1 g/L, glucose 120 mg/dL | Unable to send CSF specimen for SARS-CoV-2 RNAPCR testing | CT of the head without contrast was normal | EEG showed generalized slowing with no epileptic discharges |
| 15 | 25 | N/A | N/A | Leukocyte 1 cell/mm3, protein 0.66 g/L, glucose 10.5 mmol/L | SARS-CoV-2 RNA in CSF (-) | MRI revealed hyperintensity of the right orbital prefrontal cortex adjacent to the olfactory bulb, which seemed to spread towards the right mesial prefrontal cortex and to the right caudate nucleus | EEG showed repetitive 1 Hz rhythmic bursts over the right frontal region, suggestive of a non-convulsive status epilepticus |
| 16 | 26 | CT showed multiple subpleural ground glass opacities | WBC 26.53 × 109/L, PLT 202 × 109/L; CRP 135 mg/L; D-dimer 6.27 mg/L; LDH 560 IU/L; IL-6 481 pg/mL; ferritin 1763 ng/mL | Protein 0.376 g/L，glucose 130 mg/dL, cell count 0, CSF IgG mg/L -, IgG index -, AlbQ -, oligoclonal band - | SARS-CoV-2 RNA in CSF (-) | MRI findings showing cortical or white matter hyperintensities, contrast enhancement, and sulcal hemorrhagic features, all of which are considered compatible with meningoencephalitis | N/A |
| 17 | 26 | CT showed multiple subpleural ground glass opacities | WBC 20.21 × 109/L, PLT 540 × 109/L; CRP 82.9 mg/L, D-dimer 6.6 mg/L, LDH 304 IU/L, IL-6 -pg/mL, ferritin 2918 ng/mL | Protein 0.732 g/L，glucose 201 mg/dL, cell count 0, CSF IgG mg/L 4.27, IgG index 0.330, AlbQ 13.5, oligoclonal band none | SARS-CoV-2 RNA in CSF (-) | MRI findings showing cortical or white matter hyperintensities, contrast enhancement, and sulcal hemorrhagic features | N/A |
| 18 | 26 | CT showed multiple subpleural ground glass opacities | WBC 17.081 × 109/L, PLT 140 × 109/L, CRP 32.7 mg/L, D-dimer 0.73 mg/L, LDH 414 IU/L, IL-6 -pg/mL, ferritin 896 ng/mL | Protein 0.657 g/L，glucose 121 mg/dL, cell count 0, CSF IgG mg/L 4.68, IgG index 0.45, AlbQ 8.87, oligoclonal band none | SARS-CoV-2 RNA in CSF (-) | MRI was normal | N/A |
| 19 | 26 | CT showed multiple subpleural ground glass opacities | WBC 11.49 × 109/L, PLT 660 × 109/L, CRP 142.2 mg/L, D-dimer 0.91 mg/L, LDH 271 IU/L, IL-6 -pg/mL, ferritin 612 ng/mL | Protein 0.131 g/L，glucose 120 mg/dL, cell count 0, CSF IgG 3.23 mg/L, IgG index 0.780, AlbQ 5.14, oligoclonal band none | SARS-CoV-2 RNA in CSF (-) | MRI was normal | N/A |
| 20 | 26 | CT showed multiple subpleural ground glass opacities | WBC 42.70 × 109/L, PLT 299 × 109/L, CRP 732.3 mg/L, D-dimer 6.97 mg/L, LDH 709 IU/L, IL-6 510 pg/mL, ferritin 5235 ng/mL | Protein 0.52 g/L, glucose 67 mg/dL, cell count 0, CSF IgG 6.66 mg/L, IgG index 0.380, AlbQ 14.1, oligoclonal band none | SARS-CoV-2 RNA in CSF (-) | MRI was normal | N/A |
| 21 | 26 | CT showed multiple subpleural ground glass opacities | WBC 17.83 × 109/L, PLT 664 × 109/L, CRP 431.8 mg/L, D-dimer 7.93 mg/L, LDH 1110 IU/L, IL-6 9192 pg/mL, ferritin 555 ng/mL | Protein 0.57g/L, glucose 59 mg/dL, cell count 0, CSF IgG 5.71 mg/L, IgG index 0.520, AlbQ 10.0, oligoclonal band none | SARS-CoV-2 RNA in CSF (-) | MRI findings showing cortical or white matter hyperintensities, contrast enhancement, and sulcal hemorrhagic features | N/A |
| 22 | 33 | X-ray and CT were normal | N/A | Bacterial culture and herpes simplex virus type 1 (-) | SARS-CoV-2 RNA in CSF (+) | N/A | N/A |
| 23 | 27 | X-ray showed moderate bilateral interstitial pneumonia | High D-dimer 0.968 mg/L | Lymphocytic pleocytosis 18 cells/mm3, protein 69.6 mg/dL; oligoclonal bands (-) | SARS-CoV-2 RNA in CSF (-) | MRI with gadolinium contrast did not reveal any significant alterations or contrast-enhanced areas | EEG exhibited generalized slowing, with decreased reactivity to acoustic stimuli |
| 24 | 28 | N/A | N/A | Protein 0.466 g/L, glucose 59 mg/dL, cell count 17 cells/mm3, lymphocyte 97%，anti-NMDA antibodies(-) | SARS-CoV-2 RNA in CSF (-) | MRI was normal | EEG revealed nonconvulsive, focal status epilepticus (abundant bursts of anterior low-medium voltage irregular spike-and waves superimposed on an irregularly slowed theta background); a follow-up EEG 24 h after admission showed a moderate theta background slowing, without epileptiform features |
| 25 | 28 | N/A | N/A | High lymphocytic pleocytosis, iral/bacterial pathogens (-) | SARS-CoV-2 RNA in CSF (-) | MRI was normal | N/A |
| 26 | 29 | N/A | CRP 44.8 mg/L; ferritin 1414 ng/mL; D-dimer 0.625 mg/L; LDH 1016 U/L | WBC count 8 cells/mm3; protein 0.2 g/L; oligoclonal band test (-) | SARS-CoV-2 RNA in CSF (-) | CT showed hypodensity of the splenium of the corpus collosum | EEG showed mild diffuse slowing |
| 27 | 29 | N/A | CRP 31.3 mg/L; ferritin 1192 ng/mL; D-dimer 0.494 mg/L; LDH 900 U/L | WBC count 2 cells/mm3; protein 0.19 g/L; oligoclonal band test (-) | SARS-CoV-2 RNA in CSF (-) | Axial T2 of MRI showed signal changes of the genu and corpus collosum (top) and bilateral centrum semiovale with restricted diffusion (bottom) | EEG showed diffuse slow activity |
| 28 | 30 | CT showed multiple ground-glass opacities with multiple fibrous cord-like shadows in both lungs | WBC 3.3 × 109/L, lymphocyte 24.4%; neutrophil 62.8%; CRP 10.74 mg/L | Pressure 200 cmH2O, cell count 1 cell/mm3, protein 0.275 g/L, glucose 3.14 mmol/L; chloride 123 mmol/L | SARS-CoV-2 RNA in CSF (-) | CT did not reveal significant abnormalities | N/A |
| 29 | 31 | CT showed multiple subpleural ground glass opacities | N/A | Bacteria/HSV type 1 and 2/varicella zoster virus/West Nile virus (-) | Unable to test SARS CoV-2 in the CSF | MRI showed acute necrotizing encephalitis were seen in the bilateral thalami, medial temporal lobes, and sub-insular regions | N/A |
| 30 | 18 | N/A | N/A | N/A | SARS-CoV-2 RNA in CSF (+) | CT was normal | N/A |
| 31 | 33 | N/A | D-dimer 1.8 mg/L | CSF matched oligoclonal band | SARS-CoV-2 RNA in CSF (-) | MRI brain normal | N/A |
| 32 | 33 | N/A | D-dimer 1.599 mg/L | CSF protein raised, oligoclonal band test (-) | SARS-CoV-2 RNA in CSF (-) | MRI brain: T2 hyperintense signal changes in upper pons, limbic lobes, medial thalami and subcortical  cerebral white matter | N/A |

NA: Not available; CT: Computed tomography; EEG: Electroencephalography; CSF: Cerebrospinal fluid; MRI: Magnetic resonance imaging; FLAIR: Fluid-attenuated inversion recovery; WBC: White blood cell; N: Neutrophils; L: Lymphocyte; PLT: Platelet; CRP: C-reactive protein; GGT: Gamma glutamyl transferase; ALT: Alanine aminotransferase; SCC: Splenium of corpus callosum.

**Table 4 Auxiliary examination of the 32 coronavirus disease-19 patients with encephalitis/meningitis**

|  |  |
| --- | --- |
| **Characteristic** | **Value (*n* = 32)** |
| Subtype, *n* (%) |  |
| Encephalitis | 19 (59.36) |
| Meningitis | 5 (15.63) |
| Meningoencephalitis | 5 (15.63) |
| Encephalomyelitis | 2 (6.25) |
| Rhombencephalitis | 1 (3.13) |
| Myelitis | 1 (3.13) |
| Primary target identified by neuroimaging, *n* (%) |  |
| Temporal lobe | 5 (15.63) |
| White matter | 4 (12.5) |
| Corpus callosum | 3 (9.38) |
| Frontal lobe | 3 (9.38) |
| Cervical spinal cord | 3 (9.38) |
| Thalami | 3 (9.38) |
| Cortical | 2 (6.25) |
| Limbic lobe | 1 (3.13) |
| Brain stem | 1 (3.13) |
| Upper pons | 1 (3.13) |
| Hippocampus | 1 (3.13) |
| Insular lobe | 1 (3.13) |
| Lateral ventricle | 1 (3.13) |
| Leptomeningeal | 1 (3.13) |
| Pontine | 1 (3.13) |
| Right cerebral hemisphere | 1 (3.13) |
| Supratentorial | 1 (3.13) |
| Chest radiogram, *n* (%) |  |
| Negative/total | 4/22 (18.18) |
| Positive/total | 18/22 (81.82) |
| Not available/total | 8/30 (26.67) |
| Blood test, *n* (%) |  |
| WBC count (low/normal) | 6/21 (28.57) |
| WBC count (high) | 10/21 (47.62) |
| Lymphopenia (low) | 4/21 (19.05) |
| CRP (high) | 14/21 (66.67) |
| D-dimer (high) | 12/21 (57.14) |
| Ferritin (high) | 8/21 (38.1) |
| IL-6 (high) | 1/21 (4.76) |
| procalcitonin (high) | 1/21 (4.76) |
| ANA (positive) | 1/21 (4.76) |
| N/A | 11 (3.13) |
| Results of CSF analysis, *n* (%) |  |
| Increased pressure /total | 2/5 (40) |
| Increased protein level /total | 13/22 (59.09) |
| Increased white-cell count level/total | 9/23 (39.13) |
| Ab anti NMDAR (positive), *n* (%) | 1 (3.13) |
| Oligoclonal band test (positive), *n* (%) | 1 (3.13) |
| Neuroimaging, *n* (%) |  |
| Negative/total | 12/31 (38.71) |
| Positive/total | 19/31 (61.29) |
| Not available | 1 (3.13) |
| Results of EEG, *n* (%) |  |
| Diffuse slow wave/total | 8/10 (80) |
| Focal epileptic wave/total | 2/10 (20) |
| Generalized delta activity/total | 1/10 (20) |
| N/A | 20 (62.5) |
| Treatment modality, *n* (%) |  |
| Antibiotics/total | 22/28 (78.57) |
| Antiretroviral drug/total | 14/28 (50) |
| Hydroxychloroquine/total | 12/28 (42.86) |
| Corticoid/total | 7/28 (25) |
| IVIg/total | 6/28 (21.43) |
| Plasmapheresis treatment/total | 6/28 (21.43) |
| Anticonvulsant medications/total | 6/28 (21.43) |
| Surgery/total | 1/28 (3.57) |
| Interleukin-1 receptor antagonist/total | 1/28 (3.57) |
| Traditional Chinese medicine/total | 1/28 (3.57) |
| Not available/total | 4/32 (12.5) |
| Outcome and prognosis, *n* (%) |  |
| Good | 21/32 (65.63) |
| Poor | 5/32 (15.64) |
| Dead | 3/32 (9.38) |
| Not available | 3/32 (9.38) |

WBC: White blood cell; CRP: C-reactive protein; IL-6: Interleukin-6; CSF: Cerebrospinal fluid; EEG: Electroencephalography; IVIg: Intravenous immune globulin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**